{
  "$schema": "folio-library-document/v1",
  "id": "10665-94830",
  "title": "WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention",
  "variant": "pdf",
  "pages": 60,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "Lists of participants",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-lists-of-participants"
    },
    {
      "level": 1,
      "title": "Process for managing declarations and conflicts of interest",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-process-for-managing-declarations-and-conflicts"
    },
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 12,
      "pageLabel": "x",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-acknowledgements"
    },
    {
      "level": 1,
      "title": "Acronyms and abbreviations",
      "number": null,
      "page": 13,
      "pageLabel": "xi",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-acronyms-and-abbreviations"
    },
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 14,
      "pageLabel": "xii",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-executive-summary"
    },
    {
      "level": 1,
      "title": "Screen-and-treat strategy summary recommendations",
      "number": null,
      "page": 16,
      "pageLabel": "xiv",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-screen-and-treat-strategy-summary-recommendation"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "1",
      "page": 19,
      "pageLabel": "1",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-006-1-introduction"
    },
    {
      "level": 2,
      "title": "Target audience",
      "number": null,
      "page": 20,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-007-target-audience"
    },
    {
      "level": 2,
      "title": "Purpose",
      "number": null,
      "page": 20,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-008-purpose"
    },
    {
      "level": 1,
      "title": "Methods",
      "number": "2",
      "page": 22,
      "pageLabel": "4",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-009-2-methods"
    },
    {
      "level": 2,
      "title": "Guideline groups",
      "number": null,
      "page": 22,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-guideline-groups"
    },
    {
      "level": 2,
      "title": "Formulating questions and determining outcomes",
      "number": null,
      "page": 22,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-formulating-questions-and-determining-outcomes"
    },
    {
      "level": 2,
      "title": "Synthesis of the evidence and preparation of evidence profiles",
      "number": null,
      "page": 23,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-synthesis-of-the-evidence-and-preparation-of-evi"
    },
    {
      "level": 2,
      "title": "Modelling of health outcomes",
      "number": null,
      "page": 24,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-modelling-of-health-outcomes"
    },
    {
      "level": 2,
      "title": "Development of the recommendations",
      "number": null,
      "page": 25,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-development-of-the-recommendations"
    },
    {
      "level": 2,
      "title": "Guideline review and approval process",
      "number": null,
      "page": 26,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-015-guideline-review-and-approval-process"
    },
    {
      "level": 1,
      "title": "Recommendations",
      "number": "3",
      "page": 27,
      "pageLabel": "9",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-016-3-recommendations"
    },
    {
      "level": 2,
      "title": "Important considerations that apply to all screen-and-treat recommendations",
      "number": null,
      "page": 27,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-017-important-considerations-that-apply-to-all-scree"
    },
    {
      "level": 2,
      "title": "Screen-and-treat recommendations",
      "number": null,
      "page": 28,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-018-screen-and-treat-recommendations"
    },
    {
      "level": 1,
      "title": "Research gaps and further considerations",
      "number": "4",
      "page": 34,
      "pageLabel": "16",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-019-4-research-gaps-and-further-considerations"
    },
    {
      "level": 1,
      "title": "Use of the guideline",
      "number": "5",
      "page": 36,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-020-5-use-of-the-guideline"
    },
    {
      "level": 2,
      "title": "Guideline dissemination",
      "number": null,
      "page": 36,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-021-guideline-dissemination"
    },
    {
      "level": 2,
      "title": "Guideline evaluation",
      "number": null,
      "page": 36,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-022-guideline-evaluation"
    },
    {
      "level": 2,
      "title": "Guideline update",
      "number": null,
      "page": 37,
      "pageLabel": "19",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-023-guideline-update"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 38,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-024-references"
    },
    {
      "level": 1,
      "title": "Declarations of Interest",
      "number": "Annex 1",
      "page": 40,
      "pageLabel": "22",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-025-annex-1-declarations-of-interest"
    },
    {
      "level": 1,
      "title": "Decision-making flowchart for screen-and-treat strategies",
      "number": "Annex 2",
      "page": 43,
      "pageLabel": "25",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-026-annex-2-decision-making-flowchart-for-screen-and"
    },
    {
      "level": 1,
      "title": "Flowcharts for screen-and-treat strategies (negative or unknown HIV status)",
      "number": "Annex 3",
      "page": 44,
      "pageLabel": "26",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-027-annex-3-flowcharts-for-screen-and-treat-strategi"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "number": null,
      "page": 44,
      "pageLabel": "26",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-028-screen-with-an-hpv-test-and-treat-with-cryothera"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "number": null,
      "page": 45,
      "pageLabel": "27",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-029-screen-with-an-hpv-test-followed-by-via-and-trea"
    },
    {
      "level": 2,
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "number": null,
      "page": 46,
      "pageLabel": "28",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-030-screen-with-via-and-treat-with-cryotherapy-or-le"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "number": null,
      "page": 47,
      "pageLabel": "29",
      "confidence": 0.5,
      "evidence": [
        "contents"
      ],
      "source": "inferred",
      "section": "sec-031-screen-with-an-hpv-test-followed-by-colposcopy-w"
    },
    {
      "level": 2,
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "number": null,
      "page": 48,
      "pageLabel": "30",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-032-screen-with-cytology-followed-by-colposcopy-with"
    },
    {
      "level": 1,
      "title": "Flowcharts for screen-and-treat strategies (HIV-positive status or unknown HIV status in areas with high endemic HIV infection)",
      "number": "Annex 4",
      "page": 49,
      "pageLabel": "31",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-033-annex-4-flowcharts-for-screen-and-treat-strategi"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "number": null,
      "page": 49,
      "pageLabel": "31",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-034-screen-with-an-hpv-test-and-treat-with-cryothera"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "number": null,
      "page": 50,
      "pageLabel": "32",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-035-screen-with-an-hpv-test-followed-by-via-and-trea"
    },
    {
      "level": 2,
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "number": null,
      "page": 51,
      "pageLabel": "33",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-036-screen-with-via-and-treat-with-cryotherapy-or-le"
    },
    {
      "level": 2,
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "number": null,
      "page": 52,
      "pageLabel": "34",
      "confidence": 0.5,
      "evidence": [
        "contents"
      ],
      "source": "inferred",
      "section": "sec-037-screen-with-an-hpv-test-followed-by-colposcopy-w"
    },
    {
      "level": 2,
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "number": null,
      "page": 53,
      "pageLabel": "35",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-038-screen-with-cytology-followed-by-colposcopy-with"
    },
    {
      "level": 1,
      "title": "Search strategies for evidence reviews",
      "number": "Annex 5",
      "page": 54,
      "pageLabel": "36",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-039-annex-5-search-strategies-for-evidence-reviews"
    },
    {
      "level": 1,
      "title": "PRISMA flow diagram for inclusion and exclusion of studies for evidence reviews",
      "number": "Annex 6",
      "page": 56,
      "pageLabel": "38",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-040-annex-6-prisma-flow-diagram-for-inclusion-and-ex"
    },
    {
      "level": 1,
      "title": "Reference list of all studies included in the evidence reviews",
      "number": "Annex 7",
      "page": 57,
      "pageLabel": "39",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-041-annex-7-reference-list-of-all-studies-included-i"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "i",
      "labelEnd": "v",
      "words": 734,
      "summary": {
        "text": "The front matter of the 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, with the cover, cataloguing and copyright page (ISBN 978 92 4 154869 4) and the table of contents. The contents also point to online supplemental GRADE evidence tables for women of negative or unknown HIV status and for women with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "precancerous lesions",
          "heading": false
        },
        {
          "term": "screen-and-treat recommendations",
          "heading": false
        },
        {
          "term": "screen-and-treat strategies",
          "heading": false
        },
        {
          "term": "precancerous conditions",
          "heading": false
        },
        {
          "term": "cytology followed",
          "heading": false
        },
        {
          "term": "hpv test",
          "heading": false
        },
        {
          "term": "cryotherapy",
          "heading": false
        },
        {
          "term": "leep",
          "heading": false
        }
      ],
      "extract": "WHO guidelines WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention Test Asymptomatic women Test + Test - Treat Follow-up WHO guidelines WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention WHO Library Cataloguing-in-Publication Data WHO guidelines for screening and treatment of precancerous lesions for cervical cancer",
      "extractCut": true,
      "blocks": [
        "library/10665-94830/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-lists-of-participants",
      "number": null,
      "title": "Lists of participants",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 11,
      "labelStart": "v",
      "labelEnd": "ix",
      "words": 740,
      "summary": {
        "text": "Lists the people involved in developing the guideline, beginning with the WHO Steering Group drawn from headquarters, regional and country offices. It continues with members of the other guideline groups and external reviewers from ministries, universities, cancer agencies and NGOs around the world. Each entry gives the person's unit or institution and location.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "department obstetrics",
          "heading": false
        },
        {
          "term": "cancer epidemiology",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "cancer institute",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "silvana luciani",
          "heading": false
        },
        {
          "term": "national cancer",
          "heading": false
        },
        {
          "term": "atomic energy",
          "heading": false
        }
      ],
      "extract": "WHO Steering Group Nathalie Broutet (Lead) Reproductive Health and Research WHO Headquarters Jean-Marie Dangou Disease Prevention and Control WHO Regional Office for Africa Ibtihal Fadhil Noncommunicable Diseases WHO Regional Office for the Eastern Mediterranean Gunta Lazdane Sexual and Reproductive Health WHO Regional Office for Europe Silvana Luciani Cancer Prevention and Control WHO Regional Office for the",
      "extractCut": true
    },
    {
      "id": "sec-001-process-for-managing-declarations-and-conflicts",
      "number": null,
      "title": "Process for managing declarations and conflicts of interest",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "ix",
      "labelEnd": "x",
      "words": 477,
      "summary": {
        "text": "Recounts how the guideline arose from a 2010 decision to update WHO's 2006 guide to comprehensive cervical cancer control, and how the guideline groups developed PICO questions, outcomes and a modelling approach in 2011–2012. It notes that the guideline covers screening and treatment of precancerous lesions, not HPV vaccination, although the section title refers to managing conflicts of interest.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "declared interests",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "precancerous lesions",
          "heading": false
        },
        {
          "term": "conflicts",
          "heading": true
        },
        {
          "term": "joint sessions",
          "heading": false
        },
        {
          "term": "erg",
          "heading": false
        },
        {
          "term": "draft recommendations",
          "heading": false
        },
        {
          "term": "modelling exercise",
          "heading": false
        }
      ],
      "extract": "In September 2010, the External Review Group (ERG) met to decide on the update of Comprehensive cervical cancer control: a guide to essential practice (C4-GEP), which was originally published in 2006. One of the major conclusions was that the chapter on screening and treatment of precancerous lesions for cervical cancer prevention needed to be updated. This group also made recommendations to the World Health",
      "extractCut": true
    },
    {
      "id": "sec-002-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "x",
      "labelEnd": "xi",
      "words": 176,
      "summary": {
        "text": "Thanks the guideline groups and McMaster University staff and students who worked on the systematic review. It names the main funders, the Flanders International Cooperation Agency, France's Institut National du Cancer and the GAVI Alliance, and the editing firm.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thank",
          "heading": false
        },
        {
          "term": "alliance",
          "heading": false
        },
        {
          "term": "cancer",
          "heading": false
        },
        {
          "term": "like",
          "heading": false
        },
        {
          "term": "group",
          "heading": false
        },
        {
          "term": "work",
          "heading": false
        }
      ],
      "extract": "The World Health Organization (WHO) would like to thank the members of the Guideline Development Group and the Methodology Group for their constant availability and hard work. WHO is also very grateful to the External Review Group for making possible the development of these essential recommendations for screening and treatment of precancerous lesions for cervical cancer prevention. The names of the participants in",
      "extractCut": true
    },
    {
      "id": "sec-003-acronyms-and-abbreviations",
      "number": null,
      "title": "Acronyms and abbreviations",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "xi",
      "labelEnd": "xii",
      "words": 141,
      "summary": {
        "text": "A list of acronyms and abbreviations used in the guideline, such as CIN, HPV, LEEP, VIA and GRADE.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "acronyms",
          "heading": true
        },
        {
          "term": "lletz",
          "heading": false
        },
        {
          "term": "excision",
          "heading": false
        },
        {
          "term": "cancer",
          "heading": false
        },
        {
          "term": "leep",
          "heading": false
        },
        {
          "term": "loop",
          "heading": false
        }
      ],
      "extract": "atypical squamous cells of undetermined significance CIN cervical intraepithelial neoplasia CKC cold knife conization ERG External Review Group FICA Flanders International Cooperation Agency GAVI Alliance formerly the Global Alliance for Vaccines and Immunisation GDG Guideline Development Group GRADE Grading of Recommendations, Assessment, Development and Evaluation HPV human papillomavirus IARC International Agency",
      "extractCut": true
    },
    {
      "id": "sec-004-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 16,
      "labelStart": "xii",
      "labelEnd": "xiv",
      "words": 653,
      "summary": {
        "text": "Explains that untreated CIN2 or CIN3 lesions can progress to cervical cancer and describes the screen-and-treat approach, in which treatment follows soon after a positive screening test. It names the available screening tests (HPV test, VIA, cytology) and treatments (cryotherapy, LEEP, cold knife conization), and notes the guideline builds on earlier WHO guidance. It ends with research priorities and states that the recommendations apply to all women, with specific ones for women living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screen-and-treat strategies",
          "heading": false
        },
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "intraepithelial neoplasia",
          "heading": false
        },
        {
          "term": "cin",
          "heading": false
        },
        {
          "term": "hiv-positive status",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "test followed",
          "heading": false
        }
      ],
      "extract": "Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that may exist at any one of three stages: CIN1, CIN2, or CIN3. If left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) can progress to cervical cancer. Instead of screening and diagnosis by the standard sequence of cytology, colposcopy, biopsy, and histological confirmation of CIN, an alternative method is to use a ‘screen-and-treat’",
      "extractCut": true
    },
    {
      "id": "sec-005-screen-and-treat-strategy-summary-recommendation",
      "number": null,
      "title": "Screen-and-treat strategy summary recommendations",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 19,
      "labelStart": "xiv",
      "labelEnd": "1",
      "words": 579,
      "summary": {
        "text": "Summarizes the expert panel's recommendations on screen-and-treat strategies for cervical precancer, advising against cold knife conization and favouring cryotherapy, or LEEP when cryotherapy is unsuitable, and setting out paired preferences that generally favour an HPV test (alone or followed by VIA) over VIA alone or cytology with colposcopy, while allowing VIA in low-resource settings and existing quality cytology programmes. It also presents a decision-making flowchart that guides programme managers to a strategy based on existing programmes, resources and quality, with details referred to the annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cytology followed",
          "heading": false
        },
        {
          "term": "hpv test",
          "heading": false
        },
        {
          "term": "strategy",
          "heading": true
        },
        {
          "term": "colposcopy",
          "heading": false
        },
        {
          "term": "panel suggests",
          "heading": false
        },
        {
          "term": "expert panel",
          "heading": false
        },
        {
          "term": "screen",
          "heading": false
        },
        {
          "term": "screen-and-treat",
          "heading": true
        }
      ],
      "extract": "1 The expert panel includes all members of the WHO Steering Group, the Guideline Development Group (GDG), and the External Review Group (ERG). The expert panel1 recommends against the use of CKC as a treatment in a screen- and-treat strategy. Therefore, all screen-and-treat strategies below involve treatment with cryotherapy, or LEEP when the patient is not eligible for cryotherapy. The expert panel suggests: f f",
      "extractCut": true
    },
    {
      "id": "sec-006-1-introduction",
      "number": "1",
      "title": "Introduction",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 1012,
      "summary": {
        "text": "Introduces WHO guidelines on screening and treatment of precancerous cervical lesions, explaining that CIN2+ can progress to cancer and that cytology-based screening with colposcopy and biopsy is costly and hard to sustain in low- and middle-income countries, which makes a screen-and-treat approach attractive. It describes the components of such programmes, including HPV testing, cytology and VIA used alone or in sequence, and treatment with cryotherapy, LEEP or cold knife conization. It explains that the guideline compares benefits and harms of strategies to support countries with or without existing programmes, relates it to other WHO guidance and the updated C4-GEP, and stresses considering downstream outcomes rather than test accuracy alone.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "treat cin",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "screen-and-treat programme",
          "heading": false
        },
        {
          "term": "screen-and-treat strategies",
          "heading": false
        },
        {
          "term": "pap test",
          "heading": false
        },
        {
          "term": "treating women",
          "heading": false
        }
      ],
      "extract": "Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that may exist at any one of three stages: CIN1, CIN2, or CIN3.2 If left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) can progress to cervical cancer. It is estimated that approximately 1–2% of women have CIN2+ each year. This rate is reported to be higher in women of HIV-positive status, at 10% (1–5). The standard practice is to screen",
      "extractCut": true
    },
    {
      "id": "sec-007-target-audience",
      "number": null,
      "title": "Target audience",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 91,
      "summary": {
        "text": "Identifies the guideline's main audience as health policy-makers, managers and programme officers who choose cervical cancer prevention strategies, as well as reproductive health, STI, HIV and family planning staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "district",
          "heading": false
        }
      ],
      "extract": "This guideline is intended primarily for policy-makers, managers, programme officers, and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention, at country, regional and district levels. Individuals working in reproductive health care programmes, particularly programmes for the prevention of sexually transmitted infections (STIs) including HIV/AIDS",
      "extractCut": true
    },
    {
      "id": "sec-008-purpose",
      "number": null,
      "title": "Purpose",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 22,
      "labelStart": "2",
      "labelEnd": "4",
      "words": 229,
      "summary": {
        "text": "Sets out what the guideline contains: screen-and-treat recommendations, a decision flowchart for choosing a strategy, and flowcharts for each strategy by HIV status. It also describes the methods used and points to online GRADE evidence profiles and evidence-to-recommendation tables.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": false
        },
        {
          "term": "evidence-to-recommendation tables",
          "heading": false
        },
        {
          "term": "grade evidence",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "screen-and-treat",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "flowcharts",
          "heading": false
        }
      ],
      "extract": "This guideline provides recommendations for screen-and-treat strategies to prevent cervical cancer (Chapter 3). In addition to the recommendations, this document proposes a decision-making flowchart for choosing the best screen-and-treat strategy for a particular setting at a programme level (Annex 2); and – for use once the strategy is chosen – the screen-and-treat flowcharts for all strategies are provided,",
      "extractCut": true
    },
    {
      "id": "sec-009-2-methods",
      "number": "2",
      "title": "Methods",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 9,
      "summary": {
        "text": "A fragment stating that development followed the WHO handbook for guideline development.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "followed the WHO handbook for guideline development (11, 12).",
      "extractCut": false
    },
    {
      "id": "sec-010-guideline-groups",
      "number": null,
      "title": "Guideline groups",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 98,
      "summary": {
        "text": "Describes the three groups formed to develop the guideline: a 17-member Guideline Development Group, a 33-member External Review Group and a Methods Group from McMaster University.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": true
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "macgrade",
          "heading": false
        }
      ],
      "extract": "WHO formed a Guideline Development Group (GDG) for the screen-and-treat strategies to prevent cervical cancer, chaired by Joanna Cain. The 17 selected members provided expert clinical guidance and support throughout the guideline development process. WHO also selected an External Review Group (ERG) comprising 33 professionals, including health-care providers with experience in screening and treating CIN,",
      "extractCut": true
    },
    {
      "id": "sec-011-formulating-questions-and-determining-outcomes",
      "number": null,
      "title": "Formulating questions and determining outcomes",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 500,
      "summary": {
        "text": "Explains how the Guideline Development Group in 2011 narrowed 15 possible questions to eight through an online survey, dropping comparisons not used in practice. It then describes how outcomes such as cancer, mortality and treatment complications were ranked, with those rated important or higher included in the evidence review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cytology followed",
          "heading": false
        },
        {
          "term": "hpv test",
          "heading": false
        },
        {
          "term": "survey monkey",
          "heading": false
        },
        {
          "term": "cervical pre-cancer",
          "heading": false
        },
        {
          "term": "screen-and-treat strategies",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "outcomes",
          "heading": true
        },
        {
          "term": "questions",
          "heading": true
        }
      ],
      "extract": "outcomes In February 2011, the GDG met to discuss the questions and outcomes to address in the chapter on screen-and-treat strategies to appear in the updated C4-GEP, in order to incorporate new evidence. The GDG identified 15 potential questions to guide the evidence review for screening options and treatment strategies for cervical pre-cancer. The MG surveyed the GDG anonymously online using Survey Monkey5 to",
      "extractCut": true
    },
    {
      "id": "sec-012-synthesis-of-the-evidence-and-preparation-of-evi",
      "number": null,
      "title": "Synthesis of the evidence and preparation of evidence profiles",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 940,
      "summary": {
        "text": "Explains that, since few randomized trials link screening tests to treatment of cervical intraepithelial neoplasia (CIN) and report outcomes for all screened women, the WHO screen-and-treat recommendations for cervical pre-cancer rest instead on modelling built from reviews of screening test accuracy and of treatment effects. It describes searches of MEDLINE, EMBASE and an updated Cochrane review, inclusion criteria for diagnostic accuracy studies at low risk of bias, and independent screening and data abstraction by methodologists, with quality assessed through QUADAS and data pooled in Stata. A mathematical model then estimated the benefits and harms of each strategy for women who are HIV-positive or of unknown HIV status, with evidence quality graded by the GRADE approach and evidence-to-recommendation tables prepared for each recommendation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "screen-and-treat strategy",
          "heading": false
        },
        {
          "term": "supplemental material",
          "heading": false
        },
        {
          "term": "accuracy studies",
          "heading": false
        },
        {
          "term": "false-negative screening",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "test compared",
          "heading": false
        }
      ],
      "extract": "preparation of evidence profiles A screen-and-treat strategy is made up of two linked parts: the screening test(s) followed by treatment of CIN. The best studies to inform screen-and-treat recommendations are randomized controlled trials in which women are randomized to receive ‘screen-and-treat strategy A’ or ‘screen-and-treat strategy B’, and health outcomes of all of the women are measured and presented (even",
      "extractCut": true
    },
    {
      "id": "sec-013-modelling-of-health-outcomes",
      "number": null,
      "title": "Modelling of health outcomes",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 311,
      "summary": {
        "text": "Explains that the most accurate test is not necessarily the best choice, so a decision-analysis model was built to estimate downstream health outcomes of true and false screening results. The model calculated these for VIA, HPV testing and cytology, with assumptions set in advance and sensitivity analyses by HIV status and age.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health outcomes",
          "heading": true
        },
        {
          "term": "patient-important outcomes",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "downstream",
          "heading": false
        },
        {
          "term": "probability",
          "heading": false
        },
        {
          "term": "priori",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "assumptions",
          "heading": false
        }
      ],
      "extract": "A screening test with the highest diagnostic accuracy is not necessarily the test of choice in clinical practice. The decision to recommend a screening test needs to be justified by its impact on downstream patient-important health outcomes. Decision analysis is a powerful tool for evaluating a diagnostic or screening test on the basis of long-term patient-important outcomes when only intermediate outcomes – such as",
      "extractCut": true
    },
    {
      "id": "sec-014-development-of-the-recommendations",
      "number": null,
      "title": "Development of the recommendations",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 557,
      "summary": {
        "text": "Describes the April 2012 meeting at which the guideline groups reviewed evidence on benefits, harms, values, resources and feasibility to agree the recommendations. It notes qualitative evidence that women may fear screening and find a second visit burdensome. It explains how strong and conditional recommendations were distinguished, noting that many in this guideline are conditional.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "evidence-to-recommendation tables",
          "heading": false
        },
        {
          "term": "desirable consequences",
          "heading": false
        },
        {
          "term": "net desirable",
          "heading": false
        },
        {
          "term": "strategy outweighed",
          "heading": false
        },
        {
          "term": "erg",
          "heading": false
        },
        {
          "term": "specified strategy",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        }
      ],
      "extract": "In early 2012 (26–28 April), the GDG, the ERG and the MG met to discuss the recommendations. One member each from the GDG and the MG chaired the meeting, which was attended by experts from around the world, representing various public health and medical disciplines. To expand the geographical representativeness of the GDG, it was decided that the ERG – a large group with members representing many countries – would",
      "extractCut": true
    },
    {
      "id": "sec-015-guideline-review-and-approval-process",
      "number": null,
      "title": "Guideline review and approval process",
      "level": 2,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 349,
      "summary": {
        "text": "Describes the review process, in which questions, review protocols, evidence and draft recommendations were circulated among the steering, development and external review groups before WHO clearance. It ends with a table explaining what strong and conditional recommendations mean for patients, clinicians and policy-makers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "circulated among",
          "heading": false
        },
        {
          "term": "steering group",
          "heading": false
        },
        {
          "term": "decisions consistent",
          "heading": false
        },
        {
          "term": "decision aids",
          "heading": false
        },
        {
          "term": "gdg",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": true
        },
        {
          "term": "review",
          "heading": true
        },
        {
          "term": "erg",
          "heading": false
        }
      ],
      "extract": "The WHO screen-and-treat strategies to prevent cervical cancer underwent the following peer review process before and during development:  The questions formulated for the development of the guidelines were circulated among the WHO Steering Group, who also discussed them with the GDG. When the GDG and the WHO Steering Group had reached agreement on the questions, these were sent to the ERG.  The protocol for",
      "extractCut": true
    },
    {
      "id": "sec-016-3-recommendations",
      "number": "3",
      "title": "Recommendations",
      "level": 1,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "9",
      "labelEnd": "9",
      "words": 84,
      "summary": {
        "text": "Explains that a decision flowchart helps programme managers choose a screen-and-treat strategy, with strategy-specific flowcharts by HIV status in the annexes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unknown hiv",
          "heading": false
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "flowcharts",
          "heading": false
        }
      ],
      "extract": "To aid decision-making by programme managers, a decision-making flowchart or algorithm is provided for choosing the best screen-and-treat strategy for a particular setting at a programme level (see Annex 2). Once the strategy has been chosen, flowcharts for each strategy can be followed; these are provided in Annex 3 (negative or unknown HIV status) and Annex 4 (HIV-positive status or unknown HIV status in areas",
      "extractCut": true
    },
    {
      "id": "sec-017-important-considerations-that-apply-to-all-scree",
      "number": null,
      "title": "Important considerations that apply to all screen-and-treat recommendations",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 563,
      "summary": {
        "text": "Sets out considerations that apply to all screen-and-treat recommendations: they target women aged 30 and over, with priority for ages 30–49, while women living with HIV should be screened once sexually active after an HIV-positive result, and VIA is suited to women whose transformation zone is visible, usually under 50. Cryotherapy is the first-choice treatment, with LEEP for women ineligible under the C4-GEP criteria, and all screen-positive women should undergo VIA by a trained provider to determine treatment eligibility and exclude large lesions or suspected cancer.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screen-and-treat recommendations",
          "heading": true
        },
        {
          "term": "endocervical canal",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "hiv-positive status",
          "heading": false
        },
        {
          "term": "cryotherapy",
          "heading": false
        },
        {
          "term": "precancerous lesions",
          "heading": false
        },
        {
          "term": "unknown hiv",
          "heading": false
        },
        {
          "term": "transformation zone",
          "heading": false
        }
      ],
      "extract": "all screen-and-treat recommendations Population targeted by the recommendations The recommendations in this guideline apply to women 30 years of age (recommended age to start screening) and older because of their higher risk of cervical cancer. However, the magnitude of the net benefit will differ among age groups and may extend to younger and older women depending on their baseline risk of CIN2+. Priority should be",
      "extractCut": true
    },
    {
      "id": "sec-018-screen-and-treat-recommendations",
      "number": null,
      "title": "Screen-and-treat recommendations",
      "level": 2,
      "pageStart": 28,
      "pageEnd": 34,
      "labelStart": "10",
      "labelEnd": "16",
      "words": 3481,
      "summary": {
        "text": "Presents the screen-and-treat recommendations of the WHO guidelines on cervical pre-cancer, beginning with a strong recommendation against cold knife conization (CKC), which brings more major bleeding and premature delivery than cryotherapy or LEEP without a meaningful gain in cancer prevention. It sets screening intervals of three to five years after a negative VIA or cytology result, at least five years after a negative HPV test, within three years for women who are HIV-positive or of unknown status in high-HIV areas, and follow-up one year after treatment. Conditional recommendations favour screening with an HPV test over VIA where resources allow, and over cytology followed by colposcopy, then treating with cryotherapy or LEEP, each backed by remarks and low- or very-low-quality evidence on recurrences, cancers, deaths and overtreatment. The closing part compares an HPV test followed by colposcopy with an HPV test followed by VIA, finding fewer missed CIN2+ cases but possibly more overtreatment with colposcopy, and noting its greater resource demands and acceptability concerns.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "underwent colposcopy",
          "heading": false
        },
        {
          "term": "cytology followed",
          "heading": false
        },
        {
          "term": "colposcopy strategy",
          "heading": false
        },
        {
          "term": "fewer cancers",
          "heading": false
        },
        {
          "term": "colposcopy compared",
          "heading": false
        },
        {
          "term": "fewer cin",
          "heading": false
        },
        {
          "term": "colposcopy due",
          "heading": false
        },
        {
          "term": "fewer women",
          "heading": false
        }
      ],
      "extract": "Recommendation 1. The expert panel recommends against the use of CKC as treatment in a screen-and-treat strategy (strong recommendation, evidence) b. In the ‘HPV test followed by VIA’ strategy, women who are HPV-negative are not treated. Women who are HPV-positive all undergo VIA, which is used in this case as a second screening test to determine treatment. Women who are HPV-positive and VIA-positive will all be",
      "extractCut": true
    },
    {
      "id": "sec-019-4-research-gaps-and-further-considerations",
      "number": "4",
      "title": "Research gaps and further considerations",
      "level": 1,
      "pageStart": 34,
      "pageEnd": 36,
      "labelStart": "16",
      "labelEnd": "18",
      "words": 1010,
      "summary": {
        "text": "Notes the scarcity of randomized trials comparing screen-and-treat strategies on patient outcomes, especially for test sequences and for women living with HIV. It raises concerns about cytology programmes in weak health systems and discusses other factors such as loss to follow-up. It also mentions possible additional benefits of screening, such as detecting STIs, that studies do not consistently measure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cytology programmes",
          "heading": false
        },
        {
          "term": "hpv test",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "patient-important outcomes",
          "heading": false
        },
        {
          "term": "evaluated screen-and-treat",
          "heading": false
        },
        {
          "term": "test followed",
          "heading": false
        },
        {
          "term": "few randomized",
          "heading": false
        },
        {
          "term": "screen-and-treat strategies",
          "heading": false
        }
      ],
      "extract": "The best evidence to assess the effects of a screen-and-treat strategy is from randomized controlled trials in which women are randomly allocated to receive one or another screen-and- treat strategy and then all screened women are followed and patient-important health outcomes – such as CIN recurrence, cervical cancer and complications of treatment – are measured. We identified few randomized controlled trials that",
      "extractCut": true
    },
    {
      "id": "sec-020-5-use-of-the-guideline",
      "number": "5",
      "title": "Use of the guideline",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 36,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-021-guideline-dissemination",
      "number": null,
      "title": "Guideline dissemination",
      "level": 2,
      "pageStart": 36,
      "pageEnd": 36,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 405,
      "summary": {
        "text": "Describes plans to disseminate the guideline online, through WHO reproductive health channels and newsletters and in print to WHO's distribution lists. It mentions regional and country workshops to adapt the recommendations and notes that translations depend on funding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "library database",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "regional offices",
          "heading": false
        },
        {
          "term": "rhl",
          "heading": false
        },
        {
          "term": "cancer control",
          "heading": false
        },
        {
          "term": "health web",
          "heading": false
        },
        {
          "term": "journals",
          "heading": false
        },
        {
          "term": "subscribers",
          "heading": false
        }
      ],
      "extract": "These guidelines will be available online at the WHO Library database and there will be a link on WHO’s Sexual and Reproductive Health web page and in the WHO Reproductive Health Library (RHL), an electronic review journal.7 The publication will also be announced in the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) WHO Reproductive",
      "extractCut": true
    },
    {
      "id": "sec-022-guideline-evaluation",
      "number": null,
      "title": "Guideline evaluation",
      "level": 2,
      "pageStart": 36,
      "pageEnd": 37,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 93,
      "summary": {
        "text": "Explains that downloads, country requests for technical assistance and changes to national recommendations will be used to evaluate the guideline.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "regional offices",
          "heading": false
        },
        {
          "term": "downloads",
          "heading": false
        },
        {
          "term": "screen-and",
          "heading": false
        }
      ],
      "extract": "The number of downloads from the WHO web sites (headquarters and regional) will be used as an indicator of interest in these guidelines. We are working with the WHO regional offices to monitor requests from countries for technical assistance to use these guidelines. For this purpose, national stakeholder meetings will be organized in-country, and feedback on the clarity, feasibility, and usefulness of the",
      "extractCut": true
    },
    {
      "id": "sec-023-guideline-update",
      "number": null,
      "title": "Guideline update",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 38,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 90,
      "summary": {
        "text": "States that new evidence will be monitored and the recommendations are expected to be updated about five years after publication.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "update",
          "heading": true
        },
        {
          "term": "precancerous",
          "heading": false
        },
        {
          "term": "hoc",
          "heading": false
        }
      ],
      "extract": "The GDG will continue to work with WHO in an ad hoc manner, so that the research gaps identified during the process can be addressed. In addition, evidence published on new screening and treatment methods will be monitored so that updates to these recommendations can be considered promptly. We anticipate that around five years after the publication of these recommendations sufficient new evidence will be available",
      "extractCut": true
    },
    {
      "id": "sec-024-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 38,
      "pageEnd": 40,
      "labelStart": "20",
      "labelEnd": "22",
      "words": 541,
      "summary": {
        "text": "A list of references for the guideline, citing mainly studies of HPV testing, cervical lesions in women with HIV and a WHO costing tool.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "intraepithelial neoplasia",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cervical screening",
          "heading": false
        },
        {
          "term": "accessed august",
          "heading": false
        },
        {
          "term": "accessed october",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "low-grade abnormal",
          "heading": false
        }
      ],
      "extract": "1. Arbyn M et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 2012, 30 Suppl 5: F88–99. 2. De Vuyst H et al. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. British Journal of Cancer, 2012, 107(9):1624–1630. 3. Denny L et al. Human papillomavirus infection and cervical disease in human",
      "extractCut": true
    },
    {
      "id": "sec-025-annex-1-declarations-of-interest",
      "number": "Annex 1",
      "title": "Declarations of Interest",
      "level": 1,
      "pageStart": 40,
      "pageEnd": 43,
      "labelStart": "22",
      "labelEnd": "25",
      "words": 1347,
      "summary": {
        "text": "Discloses the declared interests of 15 of the 54 experts involved, such as conference travel support, research funding and industry links. Examples include support from EUROGIN for a speaker and PATH projects receiving donated vaccines and HPV tests from manufacturers. Each entry describes the nature of the interest in some detail.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "hpv vaccination",
          "heading": false
        },
        {
          "term": "path received",
          "heading": false
        },
        {
          "term": "cancer prevention",
          "heading": false
        },
        {
          "term": "sonichealthcare benelux",
          "heading": false
        },
        {
          "term": "qiagen",
          "heading": false
        }
      ],
      "extract": "Out of the 54 experts who participated in this work, 15 declared an interest related to cervical cancer. Although not all of these interests are specifically related to cervical cancer screening and treatment, they are nonetheless all disclosed and summarized below. Marc Arbyn was invited by the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) to speak at its 2011 conference in Lisbon.",
      "extractCut": true
    },
    {
      "id": "sec-026-annex-2-decision-making-flowchart-for-screen-and",
      "number": "Annex 2",
      "title": "Decision-making flowchart for screen-and-treat strategies",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 44,
      "labelStart": "25",
      "labelEnd": "26",
      "words": 321,
      "summary": {
        "text": "Presents a decision-making flowchart to help programme managers choose a screen-and-treat strategy based on available resources, such as costs, staff and training. It notes that other factors, such as loss to follow-up with multi-test strategies, also need to be considered.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screen-and-treat",
          "heading": true
        },
        {
          "term": "screen-and-treat strategy",
          "heading": false
        },
        {
          "term": "hpv test",
          "heading": false
        },
        {
          "term": "test followed",
          "heading": false
        },
        {
          "term": "unknown hiv",
          "heading": false
        },
        {
          "term": "hiv-positive status",
          "heading": false
        },
        {
          "term": "endemic hiv",
          "heading": false
        },
        {
          "term": "flowchart",
          "heading": true
        }
      ],
      "extract": "treat strategies This decision-making flowchart or algorithm provides a decision tree to use as a quick reference when choosing a screen-and-treat strategy at the programme level. Programme managers and decision-makers can start at the top and answer the questions accordingly to determine which screen-and-treat option is best in the context where it will be implemented. It highlights choices related to resources,",
      "extractCut": true
    },
    {
      "id": "sec-027-annex-3-flowcharts-for-screen-and-treat-strategi",
      "number": "Annex 3",
      "title": "Flowcharts for screen-and-treat strategies (negative or unknown HIV status)",
      "level": 1,
      "pageStart": 44,
      "pageEnd": 44,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 85,
      "summary": {
        "text": "Introduces the flowcharts for each screen-and-treat strategy for women of negative or unknown HIV status, noting that they do not show which strategy is preferred.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "flowcharts",
          "heading": true
        },
        {
          "term": "screen-and-treat",
          "heading": true
        },
        {
          "term": "strategies",
          "heading": true
        }
      ],
      "extract": "(negative or unknown HIV status) The following flowcharts describe the steps for each of the screen-and-treat strategies that are available. The flowcharts do not indicate which strategy is preferred. Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and to the decision-making flowchart in Annex 2. For detailed information about",
      "extractCut": true
    },
    {
      "id": "sec-028-screen-with-an-hpv-test-and-treat-with-cryothera",
      "number": null,
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 44,
      "pageEnd": 45,
      "labelStart": "26",
      "labelEnd": "27",
      "words": 116,
      "summary": {
        "text": "A flowchart for screening with an HPV test and treating positives with cryotherapy, or LEEP if ineligible, with rescreening after at least five years for negatives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "hpv test",
          "heading": true
        },
        {
          "term": "visual inspection",
          "heading": false
        },
        {
          "term": "acetic acid",
          "heading": false
        }
      ],
      "extract": "for cryotherapy When an HPV test is positive, treatment is provided. With this strategy, visual inspection with acetic acid (VIA) is used to determine eligibility for cryotherapy. Negative Determine eligibility for cryotherapy and rule out cervical cancer using visual inspection with acetic acid (VIA) Rescreen after a minimum interval of 5 years Positive Eligible for cryotherapy, treat with cryotherapy Not eligible",
      "extractCut": true
    },
    {
      "id": "sec-029-screen-with-an-hpv-test-followed-by-via-and-trea",
      "number": null,
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 45,
      "pageEnd": 46,
      "labelStart": "27",
      "labelEnd": "28",
      "words": 137,
      "summary": {
        "text": "A flowchart for screening with an HPV test followed by VIA, treating only women positive on both tests, with rescreening intervals for negative results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv test",
          "heading": true
        },
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "when not eligible for cryotherapy When an HPV test is positive, then VIA is provided as a second screening test to determine whether or not treatment is offered. Treatment is only provided if BOTH the HPV test and VIA are positive. Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the specific factors",
      "extractCut": true
    },
    {
      "id": "sec-030-screen-with-via-and-treat-with-cryotherapy-or-le",
      "number": null,
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 46,
      "pageEnd": 47,
      "labelStart": "28",
      "labelEnd": "29",
      "words": 69,
      "summary": {
        "text": "A flowchart for screening with VIA and treating with cryotherapy or LEEP, with rescreening every three to five years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "cryotherapy Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the specific factors to consider when deciding on a strategy. Eligible for cryotherapy, treat with cryotherapy Not eligible for cryotherapy, treat with LEEP Post-treatment follow-up at 1 year VIA Negative Rescreen every 3–5 years Positive",
      "extractCut": true
    },
    {
      "id": "sec-031-screen-with-an-hpv-test-followed-by-colposcopy-w",
      "number": null,
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 47,
      "pageEnd": 48,
      "labelStart": "29",
      "labelEnd": "30",
      "words": 140,
      "summary": {
        "text": "A flowchart for screening with an HPV test followed by colposcopy, with or without biopsy, and treatment of CIN2+ lesions with cryotherapy or LEEP.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "colposcopy",
          "heading": true
        },
        {
          "term": "biopsy",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        }
      ],
      "extract": "treat with cryotherapy, or LEEP when not eligible for cryotherapy Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the specific factors to consider when deciding on a strategy. 1 Women with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately.",
      "extractCut": true
    },
    {
      "id": "sec-032-screen-with-cytology-followed-by-colposcopy-with",
      "number": null,
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 48,
      "pageEnd": 49,
      "labelStart": "30",
      "labelEnd": "31",
      "words": 123,
      "summary": {
        "text": "A flowchart for screening with cytology followed by colposcopy, with or without biopsy, and treatment with cryotherapy or LEEP.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "colposcopy",
          "heading": true
        },
        {
          "term": "biopsy",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "treat with cryotherapy, or LEEP when not eligible for cryotherapy Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the specific factors to consider when deciding on a strategy. 1 Women with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately.",
      "extractCut": true
    },
    {
      "id": "sec-033-annex-4-flowcharts-for-screen-and-treat-strategi",
      "number": "Annex 4",
      "title": "Flowcharts for screen-and-treat strategies (HIV-positive status or unknown HIV status in areas with high endemic HIV infection)",
      "level": 1,
      "pageStart": 49,
      "pageEnd": 49,
      "labelStart": "31",
      "labelEnd": "31",
      "words": 93,
      "summary": {
        "text": "Introduces the flowcharts for women living with HIV or of unknown status in areas of high HIV prevalence, noting that they do not indicate a preferred strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "flowcharts",
          "heading": true
        },
        {
          "term": "screen-and-treat",
          "heading": true
        },
        {
          "term": "endemic",
          "heading": true
        }
      ],
      "extract": "(HIV-positive status or unknown HIV status in areas with high endemic HIV infection) The following flowcharts describe the steps for each of the screen-and-treat strategies that are available. The flowcharts do not indicate which strategy is preferred. Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and to the decision-making",
      "extractCut": true
    },
    {
      "id": "sec-034-screen-with-an-hpv-test-and-treat-with-cryothera",
      "number": null,
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 49,
      "pageEnd": 50,
      "labelStart": "31",
      "labelEnd": "32",
      "words": 139,
      "summary": {
        "text": "A flowchart for screening women living with HIV with an HPV test and treating positives with cryotherapy or LEEP, with rescreening within three years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "hpv test",
          "heading": true
        },
        {
          "term": "visual inspection",
          "heading": false
        },
        {
          "term": "acetic acid",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        }
      ],
      "extract": "for cryotherapy When an HPV test is positive, treatment is provided. With this strategy, visual inspection with acetic acid (VIA) is used to determine eligibility for cryotherapy. Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the factors to consider when deciding on a strategy. Negative Rescreen",
      "extractCut": true
    },
    {
      "id": "sec-035-screen-with-an-hpv-test-followed-by-via-and-trea",
      "number": null,
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 50,
      "pageEnd": 51,
      "labelStart": "32",
      "labelEnd": "33",
      "words": 132,
      "summary": {
        "text": "A flowchart from WHO's guidelines on screening and treating precancerous cervical lesions for women living with HIV or of unknown status in high HIV areas, showing a strategy of HPV testing followed by VIA, with treatment by cryotherapy or LEEP only if both tests are positive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv test",
          "heading": true
        },
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "when not eligible for cryotherapy When an HPV test is positive, then VIA is provided as a second screening test to determine whether or not treatment is offered. Treatment is only provided if BOTH the HPV test and VIA are positive. Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the factors to",
      "extractCut": true
    },
    {
      "id": "sec-036-screen-with-via-and-treat-with-cryotherapy-or-le",
      "number": null,
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 51,
      "pageEnd": 52,
      "labelStart": "33",
      "labelEnd": "34",
      "words": 96,
      "summary": {
        "text": "A flowchart for the same group of women showing a VIA screen-and-treat strategy, with rescreening after negative results, cryotherapy or LEEP for positive results, follow-up at one year and referral if cancer is suspected.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "cryotherapy Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the factors to consider when deciding on a strategy. Negative Rescreen within 3 years Positive Not eligible for cryotherapy, treat with LEEP Post-treatment follow-up at 1 year VIA (women of HIV+ status or unknown status in areas with high",
      "extractCut": true
    },
    {
      "id": "sec-037-screen-with-an-hpv-test-followed-by-colposcopy-w",
      "number": null,
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 52,
      "pageEnd": 53,
      "labelStart": "34",
      "labelEnd": "35",
      "words": 135,
      "summary": {
        "text": "A flowchart for women living with HIV or of unknown status showing HPV testing followed by colposcopy, with or without biopsy, and treatment by cryotherapy or LEEP, plus rescreening and referral steps.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "colposcopy",
          "heading": true
        },
        {
          "term": "biopsy",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        }
      ],
      "extract": "treat with cryotherapy, or LEEP when not eligible for cryotherapy Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the factors to consider when deciding on a strategy. Negative Rescreen within 3 years Eligible for cryotherapy, treat with cryotherapy Not eligible for cryotherapy, treat with LEEP",
      "extractCut": true
    },
    {
      "id": "sec-038-screen-with-cytology-followed-by-colposcopy-with",
      "number": null,
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "level": 2,
      "pageStart": 53,
      "pageEnd": 54,
      "labelStart": "35",
      "labelEnd": "36",
      "words": 150,
      "summary": {
        "text": "A flowchart showing screening by cytology followed by colposcopy, with or without biopsy, and treatment by cryotherapy or LEEP for women living with HIV or of unknown status. It sets out rescreening intervals, post-treatment follow-up and referral when cancer is suspected.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryotherapy",
          "heading": true
        },
        {
          "term": "colposcopy",
          "heading": true
        },
        {
          "term": "biopsy",
          "heading": true
        },
        {
          "term": "leep",
          "heading": true
        },
        {
          "term": "treat",
          "heading": true
        }
      ],
      "extract": "treat with cryotherapy or LEEP (when not eligible for cryotherapy) Note: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for guidance about which strategies are recommended, and for information on the factors to consider when deciding on a strategy. 1 Women with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately. Normal",
      "extractCut": true
    },
    {
      "id": "sec-039-annex-5-search-strategies-for-evidence-reviews",
      "number": "Annex 5",
      "title": "Search strategies for evidence reviews",
      "level": 1,
      "pageStart": 54,
      "pageEnd": 56,
      "labelStart": "36",
      "labelEnd": "38",
      "words": 328,
      "summary": {
        "text": "Gives the literature search strategies used for the evidence reviews on diagnostic accuracy of HPV testing, VIA, cytology and colposcopy, listing MEDLINE search terms for cervical lesions and each test. It covers searches up to January 2012.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "receiver operator",
          "heading": false
        },
        {
          "term": "dysplasia uterine",
          "heading": false
        },
        {
          "term": "receiver operating",
          "heading": false
        },
        {
          "term": "cervical dysplasia",
          "heading": false
        },
        {
          "term": "adj cervi",
          "heading": false
        },
        {
          "term": "operator characteristic",
          "heading": false
        },
        {
          "term": "roc curve",
          "heading": false
        },
        {
          "term": "neoplasia uterine",
          "heading": false
        }
      ],
      "extract": "Diagnostic test accuracy of HPV (human papillomavirus) testing, VIA (visual inspection with acetic acid), Pap testing (cytology), and colposcopy VIA compared to other tests: Search in OVID MEDLINE (up to January 2012) 1 cervical intraepithelial neoplasia/ 2 uterine cervical dysplasia/ 3 uterine cervical neoplasms/ 4 ((precancer* or pre-cancer* or neoplas* or dysplasia or lesion* or premalignan* or malignan* or",
      "extractCut": true
    },
    {
      "id": "sec-040-annex-6-prisma-flow-diagram-for-inclusion-and-ex",
      "number": "Annex 6",
      "title": "PRISMA flow diagram for inclusion and exclusion of studies for evidence reviews",
      "level": 1,
      "pageStart": 56,
      "pageEnd": 57,
      "labelStart": "38",
      "labelEnd": "39",
      "words": 216,
      "summary": {
        "text": "A PRISMA flow diagram showing how studies on screening tests and colposcopy were identified through database searches, screened and assessed for eligibility. It shows the numbers included in the meta-analysis, alongside an unpublished Cochrane review of HPV testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "total colposcopy",
          "heading": false
        },
        {
          "term": "total screening",
          "heading": false
        },
        {
          "term": "screening tests",
          "heading": false
        },
        {
          "term": "exclusion",
          "heading": true
        },
        {
          "term": "plus random",
          "heading": false
        },
        {
          "term": "random sample",
          "heading": false
        },
        {
          "term": "calculate diagnostic",
          "heading": false
        }
      ],
      "extract": "WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention Diagnostic test accuracy of HPV (human papillomavirus) testing, VIA (visual inspection with acetic acid), Pap testing (cytology), and colposcopy Records after duplicates removed (total screening tests, n=1221) (total colposcopy, n=1925) Cochrane systematic review of HPV testing compared to cytology (not published) (n=9",
      "extractCut": true
    },
    {
      "id": "sec-041-annex-7-reference-list-of-all-studies-included-i",
      "number": "Annex 7",
      "title": "Reference list of all studies included in the evidence reviews",
      "level": 1,
      "pageStart": 57,
      "pageEnd": 60,
      "labelStart": "39",
      "labelEnd": "iv",
      "words": 1113,
      "summary": {
        "text": "The reference list of studies included in the evidence reviews for the cervical cancer screening guidelines, citing mainly diagnostic accuracy studies of HPV testing, VIA, cytology and colposcopy from many countries. It ends with the publication's ISBN.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cervical cytology",
          "heading": false
        },
        {
          "term": "cervical neoplasia",
          "heading": false
        },
        {
          "term": "gynecology obstetrics",
          "heading": false
        },
        {
          "term": "cervical screening",
          "heading": false
        },
        {
          "term": "acetic acid",
          "heading": false
        },
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "visual inspection",
          "heading": false
        }
      ],
      "extract": "evidence reviews Studies on diagnostic test accuracy Agorastos T et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecologic Oncology, 2005, 96(3):714–720. Belinson J et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecologic Oncology,",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 2,
        "items": [
          "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
          "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP"
        ]
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 12,
      "items": [
        "p7: pdf-labels vii, printed v, contents v",
        "p8: pdf-labels viii, printed vi",
        "p9: pdf-labels ix, printed vii",
        "p10: pdf-labels x, printed viii",
        "p11: pdf-labels xi, printed ix, contents ix",
        "p12: pdf-labels xii, printed x, contents x",
        "p13: pdf-labels xiii, printed xi, contents xi",
        "p14: pdf-labels xiv, printed xii, contents xii",
        "p15: pdf-labels xv, printed xiii",
        "p16: pdf-labels xvi, printed xiv, contents xiv",
        "p17: pdf-labels xvii, printed xv",
        "p18: pdf-labels xviii, printed xvi"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "cervical cancer",
      "heading": true
    },
    {
      "term": "cancer screening",
      "heading": false
    },
    {
      "term": "cervical cytology",
      "heading": true
    },
    {
      "term": "screen-and-treat recommendations",
      "heading": true
    },
    {
      "term": "precancerous cervical",
      "heading": false
    },
    {
      "term": "cervical lesions",
      "heading": false
    },
    {
      "term": "screen-and-treat strategies",
      "heading": true
    },
    {
      "term": "cancer prevention",
      "heading": false
    },
    {
      "term": "screen-and-treat strategy",
      "heading": true
    },
    {
      "term": "hpv test",
      "heading": true
    },
    {
      "term": "colposcopy strategy",
      "heading": false
    },
    {
      "term": "cervical neoplasia",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iv",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "v",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "vi",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "xv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 18,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 29,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 35,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 37,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 38,
      "label": "20",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 39,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "25",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 44,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 45,
      "label": "27",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 47,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "31",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 50,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "33",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 52,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "36",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 55,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "39",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 58,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 59,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 60,
      "label": "iv",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "Prioritized questions for screening options for cervical pre-cancer 1. Should an HPV test or VIA be used to screen? 2. Should an HPV test or cytology followed by colposcopy (with or",
      "page": 22,
      "pageLabel": "4",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "2",
      "title": "Outcomes for screen-and-treat strategies identified as important for making recommendations (in order of importance) 1. Mortality from cervical cancer 2. Cervical cancer incidence",
      "page": 23,
      "pageLabel": "5",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Interpretation of strong and conditional recommendations",
      "page": 26,
      "pageLabel": "8",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p060-1",
      "file": "images/img-p060-1.webp",
      "page": 60,
      "narratives": {
        "en": "An ISBN barcode with the number 9 789241 548694 printed beneath it.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) مطبوع تحته الرقم 9 789241 548694.",
        "zh": "国际标准书号（ISBN）条形码，下方印有号码 9 789241 548694。",
        "es": "Código de barras del ISBN con el número 9 789241 548694 impreso debajo.",
        "fr": "Code-barres ISBN avec le numéro 9 789241 548694 imprimé en dessous.",
        "ru": "Штрихкод ISBN с номером 9 789241 548694, напечатанным под ним."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Interpretation of strong and conditional recommendations",
      "pages": [
        26
      ],
      "columns": [
        {
          "titles": "Implications"
        },
        {
          "titles": "Strong recommendation “We recommend… ”"
        },
        {
          "titles": "Conditional recommendation “We suggest… ”"
        }
      ],
      "rows": [
        [
          "For patients",
          "Most individuals in this situation would want the recommended course of action, and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.",
          "The majority of individuals in this situation would want the suggested course of action, but many would not."
        ],
        [
          "For clinicians",
          "Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator.",
          "Clinicians should recognize that different choices will be appropriate for each individual and that clinicians must help each individual arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful to help individuals make decisions consistent with their values and preferences."
        ],
        [
          "For policy-makers",
          "The recommendation can be adopted as policy in most situations.",
          "Policy-making will require substantial debate and involvement of various stakeholders."
        ]
      ],
      "narratives": {
        "en": "The table explains what a strong (“We recommend…”) and a conditional (“We suggest…”) recommendation imply for patients, for clinicians and for policy-makers.",
        "ar": "يوضح الجدول ما تعنيه التوصية القوية («نوصي…») والتوصية المشروطة («نقترح…») بالنسبة إلى المرضى والأطباء السريريين وراسمي السياسات.",
        "zh": "该表说明了强烈建议（“我们建议……”）和有条件建议（“我们提议……”）分别对患者、临床医生和政策制定者意味着什么。",
        "es": "La tabla explica lo que implican una recomendación fuerte («Recomendamos…») y una recomendación condicional («Sugerimos…») para los pacientes, los profesionales clínicos y los responsables de formular políticas.",
        "fr": "Le tableau explique ce qu'impliquent une recommandation forte (« Nous recommandons… ») et une recommandation conditionnelle (« Nous suggérons… ») pour les patients, les cliniciens et les responsables politiques.",
        "ru": "В таблице разъясняется, что означают сильная («Мы рекомендуем…») и условная («Мы предлагаем…») рекомендации для пациентов, клиницистов и лиц, формирующих политику."
      },
      "csv": "tables/table-1.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 42,
      "note": "contents from inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 43
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1,
      "note": "1 raster, 0 vector; 3 caption(s) read off the pages"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 2,
      "note": "drafts; backend pdfplumber 0.11.10; 3 candidate(s) dropped: under two columns or no row under the header; 52 dropped as prose cut into columns (a word cut at a quarter or more of the cell boundaries)"
    },
    {
      "kind": "references",
      "state": "found",
      "count": 20
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no glossary, definitions or abbreviations section in the entry's sections",
      "count": 0
    },
    {
      "kind": "footnotes",
      "state": "partial",
      "note": "no footnote linked to a mark; 12 mark(s) with no note found, kept for a reader to judge"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 42,
      "note": "42 of 43 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-94830"
  }
}
